Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.

Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.

The present invention relates to a method for measuring a concentration of one or more biomarker in blood from a mammal comprising: —providing a kit of parts for sampling blood comprising a lancet and a capillary, a vial comprising an extraction fluid and one or more internal standard, which is a radioisotope of one or more biomarker adapted to assess a quality and a concentration of the one or more biomarker in the blood sample, —distributing the kit of parts to the mammal, —receiving the vial comprising a blood sample inserted into the vial, —analysing the sample to determine the quality of the sample and the concentration of the one or more biomarker in the blood of the mammal by centrifuging the vial and performing a direct analysis of the supernatant.

Disclosed is a method for correlating a biomarker in a non-blood bodily fluid with the same biomarker in the blood of an individual, including: measuring, in a first period in time, the biomarker in non-blood bodily fluid and measuring the same biomarker in the blood of the same individual to establish an R ratio of [NBBF1]/[BB1], where [NBBF1] is the biomarker concentration in non-blood bodily fluid in the first period in time, and [BB1] is the biomarker concentration in the blood in the first period in time; storing the ratio in a memory; measuring, in a second period in time, the biomarker in non-blood bodily fluid to determine [NBBF2], where [NBBF2] is the biomarker concentration in the non-blood bodily fluid in the second period in time; and correlating the measured [NBBF2] with the R ratio to generate a correlated [BB2] biomarker concentration in the blood of the individual in the second period in time. Also disclosed is a device, apparatus, and method for correlating the glucose concentration in a non-blood bodily fluid such as saliva with the glucose in the blood of an individual.

In some embodiments provided herein is a method of treating a coagulopathy in a subject that is being administered or has been administered an antiplatelet agent, the method comprising: (a) determining that the subject has an abnormal result for evaluation of one or more clotting parameters; and (b) after (a), administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

In some embodiments provided herein is a method of treating a coagulopathy in a subject that is being administered or has been administered an antiplatelet agent, the method comprising: (a) determining that the subject has an abnormal result for evaluation of one or more clotting parameters; and (b) after (a), administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

Reagents are disclosed for use with potentiometric magnesium ion selective electrodes, along with kits containing same as well as methods of use thereof. Before explaining at least one embodiment of the inventive concept(s) in detail by way of exemplary drawings, experimentation, results, and laboratory procedures, it is to be understood that the inventive concept(s) is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings, experimentation and/or results.

An object of the present invention is to provide a TARC-containing composition with high storage stability. Provided is a composition including TARC (Thymus and activation-regulated chemokine) and one or more selected from the group consisting of a sugar fatty acid ester-type nonionic surfactant, a polyoxyethylene-polyoxypropylene block copolymer-type nonionic surfactant, and a polyoxyethylene alkylamine-type nonionic surfactant and being in liquid form. The aforementioned object is achieved by the composition.

A method for evaluating a sample includes obtaining a blood plasma sample prepared from human blood, conducting detection of a predetermined molecule in the blood plasma sample, and evaluating the quality of the blood plasma sample based on the intensity of the molecule acquired by the detection.

The present invention centers upon a novel “molecular amplification spike,” which is an admixture of two components, namely, an aliquot of a quantity of a molecule, composition, compound or element of interest (an “analyte”) in its natural isotopic state and an aliquot of an isotopically enriched form of the same molecule, composition, compound or element. The molecular amplification spike contains 20% natural-abundance isotope, balance enriched isotope. The molecular amplification spike may optionally contain more than 20% natural-abundance isotope, with concomitantly reduced balance of enriched isotope. Such an admixed spike, when added to a sample prior to mass spectrometric analysis of that sample, creates new and significantly improved percentage of errors and quantification or confirmation of the absence of the molecule, composition, compound or element of interest in the sample.